Capturing Chemotherapy and Radiotherapy Dose Among Breast Cancer Patients With the Utah All‐Payer Claims Database Compared With Gold‐Standard Abstraction
ABSTRACT Objective To evaluate the validity of the Utah statewide All‐Payer Claims Database (APCD), we compared breast cancer‐specific treatments and dosages with gold‐standard abstraction of medical records. Study Design In this pilot study, breast cancer treatments were abstracted by a certified t...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-11-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.70411 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850065198191214592 |
|---|---|
| author | Alzina Koric Chun‐Pin Esther Chang Shane Lloyd Mark Dodson Vikrant G. Deshmukh Michael G. Newman Ankita P. Date Jen A. Doherty Lisa H. Gren Christina A. Porucznik Benjamin A. Haaland N. Lynn Henry Mia Hashibe |
| author_facet | Alzina Koric Chun‐Pin Esther Chang Shane Lloyd Mark Dodson Vikrant G. Deshmukh Michael G. Newman Ankita P. Date Jen A. Doherty Lisa H. Gren Christina A. Porucznik Benjamin A. Haaland N. Lynn Henry Mia Hashibe |
| author_sort | Alzina Koric |
| collection | DOAJ |
| description | ABSTRACT Objective To evaluate the validity of the Utah statewide All‐Payer Claims Database (APCD), we compared breast cancer‐specific treatments and dosages with gold‐standard abstraction of medical records. Study Design In this pilot study, breast cancer treatments were abstracted by a certified tumor registrar at the Utah Cancer Registry (UCR) for patients diagnosed in 2013 with breast cancer. The abstraction of medical records was the gold standard for comparison with treatments identified in the APCD. The reliability and agreement between the treatment identified in the APCD and abstraction data were measured with sensitivity and specificity. Dose consistency was measured with the intraclass correlation coefficients (ICC). Results Compared with the 186 abstractions, the sensitivity of the APCD to identify chemotherapy agents was high: 89% for any agent, 91% for carboplatin, 83% for docetaxel, 82% for doxorubicin, or 94.7% for biologic therapy. The consistency between the chemotherapy dosage identified in the claims and the abstraction varied from 63% to 76%. For radiotherapy, the sensitivity of the claims to identify the completed radiotherapy regimen was 66%. The ICC between radiotherapy doses identified in the claims and the abstraction was 54% (95% confidence interval [CI], 48%, 67%). Conclusions Employing these novel methods, the claims were highly reliable in identifying cancer treatment agents overall, namely carboplatin, docetaxel, and trastuzumab. The claims were of moderate utility in capturing the treatment dose information. In addition to the APCD, the use of multiple data sources improved the completeness of cancer treatment information. |
| format | Article |
| id | doaj-art-2e5016ae8a6440a7be221c41b74f17b3 |
| institution | DOAJ |
| issn | 2045-7634 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-2e5016ae8a6440a7be221c41b74f17b32025-08-20T02:49:05ZengWileyCancer Medicine2045-76342024-11-011322n/an/a10.1002/cam4.70411Capturing Chemotherapy and Radiotherapy Dose Among Breast Cancer Patients With the Utah All‐Payer Claims Database Compared With Gold‐Standard AbstractionAlzina Koric0Chun‐Pin Esther Chang1Shane Lloyd2Mark Dodson3Vikrant G. Deshmukh4Michael G. Newman5Ankita P. Date6Jen A. Doherty7Lisa H. Gren8Christina A. Porucznik9Benjamin A. Haaland10N. Lynn Henry11Mia Hashibe12Division of Public Health Sciences, Department of Surgery Washington University School of Medicine St. Louis Missouri USAHuntsman Cancer Institute Salt Lake City Utah USAHuntsman Cancer Institute Salt Lake City Utah USAIntermountain Healthcare Salt Lake City Utah USAUniversity of Utah Health Sciences Center Salt Lake City Utah USAHuntsman Cancer Institute Salt Lake City Utah USAPedigree and Population Resource, Population Sciences Huntsman Cancer Institute Salt Lake City Utah USAHuntsman Cancer Institute Salt Lake City Utah USADivision of Public Health University of Utah School of Medicine Salt Lake City Utah USADivision of Public Health University of Utah School of Medicine Salt Lake City Utah USADepartment of Population Health Sciences University of Utah School of Medicine Salt Lake City Utah USADivision of Hematology and Oncology, Department of Internal Medicine University of Michigan Medical School Ann Arbor Michigan USAHuntsman Cancer Institute Salt Lake City Utah USAABSTRACT Objective To evaluate the validity of the Utah statewide All‐Payer Claims Database (APCD), we compared breast cancer‐specific treatments and dosages with gold‐standard abstraction of medical records. Study Design In this pilot study, breast cancer treatments were abstracted by a certified tumor registrar at the Utah Cancer Registry (UCR) for patients diagnosed in 2013 with breast cancer. The abstraction of medical records was the gold standard for comparison with treatments identified in the APCD. The reliability and agreement between the treatment identified in the APCD and abstraction data were measured with sensitivity and specificity. Dose consistency was measured with the intraclass correlation coefficients (ICC). Results Compared with the 186 abstractions, the sensitivity of the APCD to identify chemotherapy agents was high: 89% for any agent, 91% for carboplatin, 83% for docetaxel, 82% for doxorubicin, or 94.7% for biologic therapy. The consistency between the chemotherapy dosage identified in the claims and the abstraction varied from 63% to 76%. For radiotherapy, the sensitivity of the claims to identify the completed radiotherapy regimen was 66%. The ICC between radiotherapy doses identified in the claims and the abstraction was 54% (95% confidence interval [CI], 48%, 67%). Conclusions Employing these novel methods, the claims were highly reliable in identifying cancer treatment agents overall, namely carboplatin, docetaxel, and trastuzumab. The claims were of moderate utility in capturing the treatment dose information. In addition to the APCD, the use of multiple data sources improved the completeness of cancer treatment information.https://doi.org/10.1002/cam4.70411APCDbreast cancerchemotherapygold standardmethodsradiotherapy dose |
| spellingShingle | Alzina Koric Chun‐Pin Esther Chang Shane Lloyd Mark Dodson Vikrant G. Deshmukh Michael G. Newman Ankita P. Date Jen A. Doherty Lisa H. Gren Christina A. Porucznik Benjamin A. Haaland N. Lynn Henry Mia Hashibe Capturing Chemotherapy and Radiotherapy Dose Among Breast Cancer Patients With the Utah All‐Payer Claims Database Compared With Gold‐Standard Abstraction Cancer Medicine APCD breast cancer chemotherapy gold standard methods radiotherapy dose |
| title | Capturing Chemotherapy and Radiotherapy Dose Among Breast Cancer Patients With the Utah All‐Payer Claims Database Compared With Gold‐Standard Abstraction |
| title_full | Capturing Chemotherapy and Radiotherapy Dose Among Breast Cancer Patients With the Utah All‐Payer Claims Database Compared With Gold‐Standard Abstraction |
| title_fullStr | Capturing Chemotherapy and Radiotherapy Dose Among Breast Cancer Patients With the Utah All‐Payer Claims Database Compared With Gold‐Standard Abstraction |
| title_full_unstemmed | Capturing Chemotherapy and Radiotherapy Dose Among Breast Cancer Patients With the Utah All‐Payer Claims Database Compared With Gold‐Standard Abstraction |
| title_short | Capturing Chemotherapy and Radiotherapy Dose Among Breast Cancer Patients With the Utah All‐Payer Claims Database Compared With Gold‐Standard Abstraction |
| title_sort | capturing chemotherapy and radiotherapy dose among breast cancer patients with the utah all payer claims database compared with gold standard abstraction |
| topic | APCD breast cancer chemotherapy gold standard methods radiotherapy dose |
| url | https://doi.org/10.1002/cam4.70411 |
| work_keys_str_mv | AT alzinakoric capturingchemotherapyandradiotherapydoseamongbreastcancerpatientswiththeutahallpayerclaimsdatabasecomparedwithgoldstandardabstraction AT chunpinestherchang capturingchemotherapyandradiotherapydoseamongbreastcancerpatientswiththeutahallpayerclaimsdatabasecomparedwithgoldstandardabstraction AT shanelloyd capturingchemotherapyandradiotherapydoseamongbreastcancerpatientswiththeutahallpayerclaimsdatabasecomparedwithgoldstandardabstraction AT markdodson capturingchemotherapyandradiotherapydoseamongbreastcancerpatientswiththeutahallpayerclaimsdatabasecomparedwithgoldstandardabstraction AT vikrantgdeshmukh capturingchemotherapyandradiotherapydoseamongbreastcancerpatientswiththeutahallpayerclaimsdatabasecomparedwithgoldstandardabstraction AT michaelgnewman capturingchemotherapyandradiotherapydoseamongbreastcancerpatientswiththeutahallpayerclaimsdatabasecomparedwithgoldstandardabstraction AT ankitapdate capturingchemotherapyandradiotherapydoseamongbreastcancerpatientswiththeutahallpayerclaimsdatabasecomparedwithgoldstandardabstraction AT jenadoherty capturingchemotherapyandradiotherapydoseamongbreastcancerpatientswiththeutahallpayerclaimsdatabasecomparedwithgoldstandardabstraction AT lisahgren capturingchemotherapyandradiotherapydoseamongbreastcancerpatientswiththeutahallpayerclaimsdatabasecomparedwithgoldstandardabstraction AT christinaaporucznik capturingchemotherapyandradiotherapydoseamongbreastcancerpatientswiththeutahallpayerclaimsdatabasecomparedwithgoldstandardabstraction AT benjaminahaaland capturingchemotherapyandradiotherapydoseamongbreastcancerpatientswiththeutahallpayerclaimsdatabasecomparedwithgoldstandardabstraction AT nlynnhenry capturingchemotherapyandradiotherapydoseamongbreastcancerpatientswiththeutahallpayerclaimsdatabasecomparedwithgoldstandardabstraction AT miahashibe capturingchemotherapyandradiotherapydoseamongbreastcancerpatientswiththeutahallpayerclaimsdatabasecomparedwithgoldstandardabstraction |